Bristol Myers Squibb Co. has identified serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular, cerebrovascular, metabolic, inflammatory, neurological and immunological disorders, among others.